1	A systems serology analysis of correlates of protection against cholera
2	
3	Kirsten E. Wiens <sup>1,*</sup> , Anita S. Iyer <sup>2,3,*</sup> , Taufiqur R. Bhuiyan <sup>4</sup> , Lenette L. Lu <sup>5,6,7</sup> , Deniz Cizmeci <sup>8</sup> ,
4	Matthew J. Gorman <sup>8</sup> , Dansu Yuan <sup>8</sup> , Rachel L. Becker <sup>2</sup> , Edward T. Ryan <sup>2,3,10</sup> , Stephen B.
5	Calderwood <sup>2,3</sup> , Regina C. LaRocque <sup>2,3</sup> , Fahima Chowdhury <sup>4</sup> , Ashraful I. Khan <sup>4</sup> , Myron M.
6	Levine <sup>9</sup> , Wilbur H. Chen <sup>9</sup> , Richelle C. Charles <sup>2,3,10</sup> , Andrew S. Azman <sup>1,#</sup> , Firdausi Qadri <sup>4,#</sup> , Galit
7	Alter <sup>3,8,#</sup> , Jason B. Harris <sup>2,11,#,†</sup>
8	
9	* Contributed equally
10	# Contributed equally
11	
12	Author affiliations:
13	<sup>1</sup> Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,
14	MD, USA
15	<sup>2</sup> Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
16	<sup>3</sup> Department of Medicine, Harvard Medical School, Boston, MD, USA
17	<sup>4</sup> Infectious Diseases Division, International Centre for Diarrheoal Disease Research,
18	Bangladesh, Dhaka, Bangladesh
19	<sup>5</sup> Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine,
20	UTSW Medical Center, Dallas, TX, USA
21	<sup>6</sup> Department of Immunology, UTSW Medical Center, Dallas, TX, USA
22	<sup>7</sup> Parkland Health and Hospital System, Dallas, TX, USA
23	<sup>8</sup> Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
24	<sup>9</sup> Center for Vaccine Development and Global Health, University of Maryland School of Medicine,

Baltimore, MD, USA

- <sup>10</sup>Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston,
   MA, USA
- 28 <sup>11</sup>Department of Pediatrics, Harvard Medical School, Boston, MA, USA
- 29
- 30 **† For correspondence:** Jason B. Harris (jbharris@mgh.harvard.edu)
- 31
- 32
- 33 Abstract

34 Vibriocidal antibodies are the best characterized correlate of protection against cholera and are 35 used to gauge immunogenicity in vaccine trials. However, there is no vibriocidal titer threshold 36 associated with absolute protection against infection with Vibrio cholerae or with symptomatic 37 disease in infected individuals. While other circulating antibody responses have also been 38 associated with a decreased risk of V. cholerae infection, there has been no comprehensive 39 comparison of correlates of protection against cholera. To address this, we analyzed 58 serum 40 antibody biomarkers as correlates of protection against both V. cholerae infection and against 41 cholera diarrhea in infected individuals. The study was performed in two cohorts: (1) household 42 contacts of patients with cholera in Bangladesh, and (2) North American volunteers who were 43 vaccinated with a single dose of CVD 103-HgR live oral cholera vaccine and then challenged 44 with virulent V. cholerae O1 El Tor Inaba. In household contacts, we identified 20 antibody 45 markers that were correlated with protection against V. cholerae infection, though there was 46 overlap between distributions. Conditional random forest models identified serum antibodydependent complement deposition, targeting the V. cholerae O1 antigen, as the most predictive 47 48 individual correlate of protection from infection, while vibriocidal antibody titers were less 49 predictive. The model that most accurately predicted protection from infection included five 50 biomarkers, with a cross-validated area under the curve (cvAUC) of 79% (95% CI 73-85). 51 Similarly, in North American volunteers who were challenged with V. cholerae after vaccination,

a different five-biomarker model predicted protection from the development of cholera diarrhea
with a cvAUC of 78% (95% CI 66-91). Thus, while several new biomarkers predict protection
better than vibriocidal titers, it remains difficult to consistently predict whether an individual will
be protected from future mucosal infection or symptoms using current serologic markers.

56

#### 57 Introduction

58 Circulating antibodies that correlate with protection from infection or disease are valuable for 59 understanding whether segments of the population are likely to be protected due to prior 60 infection or vaccination. For cholera, the most well characterized and widely used correlate of 61 protection is the serum vibriocidal antibody titer (lyer and Harris, 2021). Vibriocidal titers remain 62 elevated in the blood for up to a year or longer following infection (Azman et al., 2019), but are 63 not thought to represent a mechanistic form of mucosal immunity (Iver and Harris, 2021). Serum 64 IgA antibodies specific to several Vibrio cholerae antigens are also correlated with protection 65 from infection (Harris et al., 2008; Kaisar et al., 2021). While intestinal IgA antibodies could 66 represent a direct form of protection, circulating IgA responses are short-lived following V. 67 cholerae infection (Azman et al., 2019). For all of these known correlates, there is no titer that is 68 associated with absolute protection.

69 In addition to serum vibriocidal and IgA responses, extensive household-based studies 70 conducted in Dhaka, Bangladesh have shown that age, ABO blood group, and certain species 71 in the intestinal microbiota are associated with infection and disease severity (Harris et al., 72 2008; Levade et al., 2021; Midani et al., 2018; Ritter et al., 2019; Weil et al., 2009). However, 73 taken together, these variables do not entirely account for the variation in susceptibility or 74 disease severity seen in this population. This residual variation is likely attributable to a 75 combination of individual-level risk factors, exposure histories, and unmeasured or undetected 76 immune responses. The degree to which unmeasured immune responses contribute to variation

in susceptibility is unknown, and no comprehensive comparison of the multiple known correlatesof protection against cholera has been conducted.

79

Here, our objective was to perform a comprehensive analysis of antibody-mediated correlates of protection from both *V. cholerae* infection and cholera diarrhea. Specifically, we asked: (1) Can we identify novel serum correlates of susceptibility to infection and/or cholera diarrhea after exposure to *V. cholerae* following both prior infection and vaccination? and (2) Do pre-infection biomarkers allow for accurate identification of who will be infected after exposure and/or who will go on to develop symptoms?

To this end, we conducted a systems serology analysis (Arnold and Chung, 2018; 86 87 Chung and Alter, 2017) of 58 pre-infection serum biomarkers in two cohorts of individuals that 88 were followed prospectively to monitor V. cholerae infection and cholera diarrhea. The 89 biomarkers evaluated included all previously identified antigens associated with protective 90 immunity as well as functional markers of antibody-mediated antibacterial immunity. The first 91 cohort included contacts in the household of patients who had cholera in Dhaka, Bangladesh, 92 where cholera is endemic (Levade et al., 2021; Weil et al., 2009). The second cohort consisted 93 of North American volunteers who were vaccinated with a live attenuated oral cholera vaccine 94 and subsequently challenged with V. cholerae (Chen et al., 2016). We tested single- and multi-95 biomarker panels in prediction using several machine-learning approaches. Our work identifies 96 several novel biomarkers, as well as both the utility and limitations of using serum biomarkers to 97 predict susceptibility to mucosal infection.

98

99 Results

## 100 Household contacts of index cholera cases

We included samples and data from 261 contacts of *V. cholerae* O1-Ogawa-infected cholera
cases in 180 households in Dhaka, Bangladesh. The characteristics of this cohort are shown in

- 103 Table 1. The cohort included 4 individuals who were under five years old, all of whom went on to
- 104 develop infection. 77 of the 261 contacts had a positive stool culture (i.e., became infected) after
- 105 exposure to a case in the household. Among the infected contacts, 26 were symptomatic and
- 106 51 were asymptomatic.
- 107

		Total		Infected	
Category	Group	N	%	N	%
Sex	Female	134	51.3	40	29.9
	Male	127	48.7	37	29.1
Age group	0-4	4	1.5	4	100.0
	5-17	74	28.4	25	33.8
	18-49	164	62.8	45	27.4
	50-71	19	7.3	3	15.8
Self-reported	No	251	96.2	76	30.3
history of prior cholera	Yes	10	3.8	1	10.0
Vibriocidal titer	No	226	86.6	74	32.7
≥320 upon enrollment	Yes	35	13.4	3	8.6
Index cholera	No	181	69.3	60	33.1
case received antibiotics	Yes	80	30.7	17	21.2
Relationship to	Child	48	18.4	18	37.5
index cholera	Sibling	47	18.0	15	31.9
case	Spouse	61	23.4	15	24.6
	Parent	101	38.7	29	28.7
Diarrhea	0-6 days	67	25.7	17	25.4
duration in	7-20 days	92	35.2	23	25.0
index case	14-20 days	38	14.6	12	31.6
	21-73 days	64	24.5	25	39.1

108 Table 1. Characteristics of the household contacts of index cholera cases in Dhaka, Bangladesh


109


# 110 Correlates of protection in household contacts

- 111 We examined 58 serum antibody biomarkers in household contacts upon enrollment. These
- 112 included 54 antigen-isotype specific responses measured using a multiplex bead assay: IgA,
- 113 IgA1, IgA2, IgM, IgG, IgG1, IgG2, IgG3, and IgG4 specific for V. cholerae O1 Ogawa OSP:BSA,

114 O1 Inaba OSP:BSA, toxin coregulated pilus (TcpA), cholera holotoxin (CT-HT), cholera toxin B 115 subunit (CtxB), and V. cholerae sialidase. These antigens represent dominant targets of the 116 humoral immune response following cholera (Kauffman et al., 2016) (Azman et al., 2019). We 117 also examined previous measurements of vibriocidal titers (Ritter et al., 2019) as well as three 118 previously uninvestigated measures of functional antibody responses against cholera. These 119 included measures of antibody-dependent complement deposition (ADCD), antibody-dependent 120 cellular phagocytosis (ADCP), and antibody-dependent neutrophil phagocytosis (ADNP) 121 targeting the V. cholerae O1 antigen. We verified that patients recovering from cholera mounted ADCD, ADCP and ADNP responses (Figure 1). 122


123






- 133 In single biomarker analyses, after adjusting for age and household clustering, 20 biomarkers
- 134 were elevated among household contacts that remained uninfected (Figure S1) and hence were
- 135 correlates of protection from subsequent infection. Among individual biomarkers, the risk of
- 136 becoming infected with V. cholerae O1 was particularly low in individuals with elevated ADCD,

- 137 TcpA IgG2, and TcpA IgA2 titers (Figure 2). Correlates of protection from symptoms among
- 138 infected individuals were distinct from correlates of protection from initial infection (Figure S2),
- though sample sizes were smaller (n=77) and there was substantial overlap in antibody
- 140 distributions between outcomes (Figure S1).
- 141



### 142




shown for each biomarker analyzed independently. Arrows indicate where upper confidence interval

147 extends beyond the graph. Isotype is indicated on the left and antigen on the right for binding antibody

148 titers. Biomarkers for which logistic model fitted values were very close to 1 are excluded.

In an unsupervised multivariate analysis, we found limited separation of infection outcomes using all antibody responses (Figure S3), which were generally highly correlated (Figure S4). We then used conditional random forest models, designed to handle a large number of highly correlated variables (Strobl et al., 2007), to examine which biomarkers were most important for classifying individuals by outcome. ADCD was ranked most important for classifying infections, and there were several features with higher scores than vibriocidal titers (Figure 3).



Conditional Importance of top 15 variables/biomarkers

## 155

Figure 3. Biomarkers important for classifying household contacts by infection outcome. Top 15
 biomarkers important in classifying household contacts of index cholera cases as infected (i.e., becoming
 stool culture positive) vs. uninfected (i.e., remaining stool culture negative). Biomarkers are ranked by
 importance scores calculated using conditional random forest classification models.

160

161 To test the validity of the classification models, we performed leave-one-out cross-validation for

162 models constructed using different subsets of biomarkers and age. The model that most


163 accurately predicted infection included five of the most informative biomarkers, with a cross-

validated area under the curve (cvAUC) of 79% (95% CI 73-85) (Figure 4). This corresponded

to a positive predictive value (PPV) of 0.85 and a negative predictive value (NPV) of 0.53. A

166 model including ADCD and age performed comparably (cvAUC 74% (95% CI 68-81)) with PPV

0.83 and NPV 0.52. The vibriocidal model was less predictive (cvAUC 54% (95% CI 47-61))
with PPV 0.74 and NPV 0.26 (Figure 4). These results were consistent when we performed
classification using an ensemble or "super learner" of three different classification models
(random forest, penalized logistic regression, and support vector machine) (Figure S5).



## 171

172 Figure 4. Predicting infection outcome among household contacts using different subsets of 173 biomarkers. A) Cross-validated receiver operator curves (cvROC) for classifying household contacts of 174 index cholera cases that remain uninfected vs. become infected using random forest models with different 175 subsets of biomarkers and age. "5 biomarkers" corresponds to five of the top biomarkers selected via 176 conditional importance, including ADCD, CtxB IgM, TcpA IgG2, Ogawa-OSP IgG1, and Sialidase IgG1. 177 True and false positive rates calculated using leave-one-out cross-validation. B) Cross-validated area 178 under the curve (cvAUC) corresponding to the models in A. Influence-curve based 95% confidence 179 intervals are shown for the cvAUC estimates.

180

# 181 Correlates of protection in challenged vaccine recipients

182 While household contacts of cholera cases have high risk of exposure in a real-world setting, a

- 183 limitation of this study design for examining protection is that the degree and duration of
- 184 exposure are unknown and varied among the study participants. To examine whether the
- 185 primary correlates of protection for household contacts were consistent in vaccinees and in the
- 186 setting of a controlled exposure, we replicated the analysis in a cohort of North American
- 187 volunteers that received a live attenuated oral cholera vaccine (CVD 103-HgR) and were then
- 188 challenged with approximately  $1 \times 10^5$  colony forming units of the wild type V. cholerae O1 El

- 189 Tor Inaba strain N16961 (Chen et al., 2016). This cohort included 34 individuals challenged 10
- 190 days post vaccination and 33 individuals challenged 90 days post vaccination (Table 2).

191 Participants were 18-45 years old, 16 (24%) were female, and 20 (30%) developed mild to

- 192 severe diarrhea following exposure (Table 2).
- 193


Table 2. Characteristics of North American volunteers who were vaccinated and then challenged
 with *V. cholerae*

Characteristic	Category	Ν	No qualifying	Mild	Moderate	Severe
			diarrhea			
Challenge day	10	34	29 (85.3%)	3 (8.8%)	1 (2.9%)	1 (2.9%)
post vaccination	90	33	18 (54.5%)	11 (33.3%)	2 (6.1%)	2 (6.1%)
Age group	18-25	15	12 (80%)	3 (20%)	0 (0%)	0 (0%)
	26-35	34	24 (70.6%)	7 (20.6%)	1 (2.9%)	2 (5.9%)
	36-45	18	11 (61.1%)	4 (22.2%)	2 (11.1%)	1 (5.6%)
Sex	Female	16	11 (68.8%)	3 (18.8%)	0 (0%)	2 (12.5%)
	Male	51	36 (70.6%)	11 (21.6%)	3 (5.9%)	1 (2%)

<sup>196</sup> 

198 We measured serum antibody responses for the same set of biomarkers as above, apart from 199 ADCP (which was not measured due to limited sample volumes). As with the household 200 contacts, we found no separation of vaccinees by diarrhea outcome in an unsupervised analysis 201 of day-of-challenge serum biomarkers (Figure S6) and titers were highly correlated (Figure S7). 202 In contrast to the household contacts, CT-HT IgA and CtxB IgA responses were ranked most 203 conditionally important for classifying by diarrhea status (Figure 5). As with the household 204 contacts, several features ranked higher than vibriocidal titers (Figure 3, Figure 5). Differences 205 in biomarker importance between the cohorts persisted when we restricted the household 206 contacts to the same age groups as the vaccinees (Figure S8). Relative ranking of biomarkers 207 differed when we subset the vaccinees to those challenged on either day 10 or day 90 (Figure 208 S9), though sample sizes were small in the subsets (Table 2) and uncertainty was high (Figure 209 S10).


<sup>197</sup> 



210

Figure 5. Biomarkers important for classifying vaccinees by whether they developed diarrhea following *V. cholerae* challenge. Top 15 biomarkers important in classifying vaccinees by developing either no qualifying diarrhea or mild to severe diarrhea following *V. cholerae* challenge. Biomarkers were selected using serum collected from participants on the day of challenge. Biomarkers are ranked by importance scores calculated using conditional random forest classification models.

217 We found comparable cross-validated results for the vaccinees as the household contacts. The 218 model that most accurately predicted developing cholera diarrhea included five of the top 219 biomarkers and age with cvAUC 78% (95% CI, 66-91%) with a PPV of 0.83 and NPV of 0.65 220 (Figure 6). Models that included only age and either CT-HT IgA2 or CtxB IgA performed 221 comparably, followed by vibriocidal titers and then ADCD and TcpA IgA. The fold-increase in 222 vibriocidal titers by day 10 following vaccination was less predictive of cholera diarrhea than 223 day-of-challenge titers (Figure S11). These results were consistent when classification was 224 performed using the ensemble model (Figure S12). Furthermore, the 5-biomarker fitted with the 225 household contact data (Figure 4) performed nearly as well when predicting cholera diarrhea in 226 the vaccinees with cvAUC 77% (95% CI, 64-90%) (Figure S13). In contrast, the 5-biomarker 227 model fitted with the vaccinee data (Figure 6) performed poorly when predicting V. cholerae 228 infection in the household contacts with cvAUC 60% (95% CI, 52-67%) (Figure S13).



229

Figure 6. Predicting whether vaccinees develop diarrhea using different subsets of biomarkers. A)
Cross-validated receiver operator curves (cvROC) for classifying vaccinees that develop diarrhea vs.
those that do not using random forest models with different subsets of biomarkers and age. "5
biomarkers" corresponds to five of the top biomarkers selected via conditional importance, including CTHT IgA, CtxB IgA, CT-HT IgA2, TcpA IgA, and Sialidase IgA2. True and false positive rates calculated
using leave-one-out cross-validation. B) Cross-validated area under the curve (cvAUC) corresponding to
the models in A. Influence-curve based 95% confidence intervals are shown for the cvAUC estimates.

### 238 Discussion

239 Vibriocidal antibody titers are considered the best accepted correlate of protection against V. 240 cholerae and are used as a proxy for predicting vaccine efficacy in Phase I/II clinical trials for 241 cholera vaccines (Iver and Harris, 2021). Using a systems serology approach, we identified 19 242 additional biomarkers that were also associated with reduced risk of infection in household 243 contacts of patients with cholera. In models evaluating multiple immune measures, vibriocidal 244 antibodies were less important in classifying risk of infection than other markers. This was true 245 both in a cohort of household contacts and in a cohort of challenged cholera vaccinees. Our 246 finding, that numerous markers individually and in combination are more predictive of protection 247 from infection than vibriocidal titers, challenges the current standard that vibriocidal antibodies 248 are indeed the best available correlate of protection against cholera.

249 Though we identified many antibody correlates of protection against cholera, our ability 250 to distinguish between immunologically protected and susceptible individuals using current 251 serologic markers was not perfect. This may reflect non-immunologic factors that influence the 252 outcome of infection, or the inherent challenges involved in using serum biomarkers to predict 253 mucosal immunity. Some of the unexplained protection may be attributable to V. cholerae O1-254 specific memory B cell responses, which have been shown to be associated with protection 255 even in the absence of elevated levels of circulating antibodies (Haney et al., 2018; Patel et al., 256 2012). In addition, secretory IgA and innate immune signaling at the mucosal surface play 257 important roles in modulating susceptibility (Karlsson et al., 2013; Weil et al., 2019) but cannot 258 be measured directly in serum. Systems serology approaches to distinguishing active vs. latent 259 tuberculosis (Lu et al., 2016) and mild vs. severe SARS-CoV-2 (Bartsch et al., 2021) were more 260 predictive than ours, with cross-validated accuracies of up to 91-97% for certain outcomes. In 261 contrast, a systems serology analysis of protection from typhoid fever found predictive 262 accuracies similar to ours (73-86%) (Jin et al., 2020). These discrepancies could reflect inherent 263 differences in immunity in the lungs compared to the gut, or differences between intracellular 264 and extracellular pathogens, and how those responses correlate with circulating antibodies. 265 Despite lack of a perfect predictive model, we were able to identify robust correlates of 266 protection in cholera. Some of these correlates had been identified previously (lyer and Harris, 267 2021) while others, such as ADCD, are novel. Interestingly, ADCD was the single most 268 predictive single marker of protection in household contacts and shares several similarities the 269 vibriocidal titer marker. Both ADCD and vibriocidal titers are complement-dependent measures 270 of functional antibody-mediated immunity. However, while vibriocidal titers reflect the 271 downstream bactericidal activity of antibodies which activate complement via the classical 272 pathway, ADCD is a bead-based, antigen-specific measure of C3 binding to V. cholerae O1-273 targeted antibodies. While there is ongoing debate whether circulating antibodies, transuded

274 from the vascular compartment, could mediate complement dependent killing of V. cholerae and

other enteric pathogens on the surface of the intestinal mucosa (Iyer and Harris, 2021), it is
notable that these predictive markers both implicate complement-dependent antibody
responses. Considering this, and that exposure of *V. cholerae* to O-antigen binding IgG induces
bacterial responses which protect against complement mediated killing (Baranova et al., 2018),
raises the possibility that complement could play a role in protective immunity against *V. cholerae*.

281 In this study, we did not find a 'universal signature' or single set of biomarkers that was 282 optimal for classifying outcomes across both cohorts (household contacts and challenged 283 vaccinees) or outcomes (infection and illness). However, the model which best predicted 284 susceptibility in household contacts also predicted susceptibility in vaccinees with similar 285 accuracy. In contrast, a model trained to predict protection in challenged vaccinees in a 10 to 286 90-day window did not accurately predict susceptibility among household contacts. This may 287 reflect that a model trained in a single experimental setting is less likely to identify broadly 288 applicable correlates of protection than models based on observed conditions in a cholera-289 endemic population. In other words, the household contact model may reflect correlates of 290 protection which are applicable across a wider range of circumstances (e.g., different times 291 between exposures, different strains of the bacteria, different populations) and to reflect multiple 292 immune pathways which may lead to protection against cholera.

293 This study has limitations. We do not know if uninfected household contacts of index 294 cholera cases were exposed to sufficient V. cholerae through contaminated water or food 295 sources to be considered exposed yet protected. This may contribute to the variation seen in 296 this cohort and may explain why predictive accuracy was slightly higher for vaccinees with 297 known exposure status. In addition, we relied on previous measurements of vibriocidal titers in 298 this cohort. In a subset of samples where we were able to repeat the vibriocidal assays, we 299 found that the old and new responses were highly correlated (Figure S14) and gave comparable 300 results in prediction (Figure S15). This suggests that changes over time in sample quality or

handling may not have affected the other biomarkers but does not eliminate the possibility.
Lastly, the conditional permutation method we used to rank biomarkers in the random forest
models has some inherent instability and may give preference to highly correlated variables
(Debeer and Strobl, 2020). However, the consistency of the results from this approach with that
of ensemble of three models (Figure S5, Figure S12) supports the robustness of our overall
conclusions.

307 In summary, we have identified a set of serum biomarkers that can be used to monitor 308 susceptibility to V. cholerae infection and symptoms, with varying sensitivity and specificity. 309 These new markers could allow for flexibility in designing studies of population susceptibility to 310 infection, provided that predictive accuracy metrics are used to adjust final estimates. In 311 addition, future studies could examine whether antibody markers in alternative samples such as 312 stool and/or saliva correlate with mucosal immunity and allow for more accurate prediction. 313 Finally, these findings illustrate the need to design better observational studies that allow us to 314 more accurately measure V. cholerae exposure, for example by including questionnaires on 315 frequency and duration of interactions with index cases in addition to measures of 316 infectiousness in household surveys (Coit et al., 2019). Such analyses would provide important 317 insights into how immunity and other risk factors contribute to both individual outcomes and 318 secondary transmission.

319

#### 320 Materials and Methods

### 321 Study populations and sample collection

322 Case-ascertainment cohorts in Dhaka, Bangladesh

323 We included samples and data from participants in Dhaka, Bangladesh from Dec. 2006 to Sept.

324 2018 (Ritter et al., 2019). Symptom histories, blood, and fecal samples were collected

325 prospectively from household contacts of hospital-ascertained cholera cases in Dhaka,

Bangladesh. Households were defined as individuals who shared the same cooking pot for ≥3

327 days. Stool samples and rectal swabs were tested for presence of *V. cholerae*. Blood 328 specimens were tested for serum antibody titers and ABO blood group. For this study, we 329 included 261 household contacts who were stool negative upon enrollment, did not report 330 diarrhea symptoms in the preceding week or at enrollment, and had sufficient sample material 331 for laboratory analyses. We excluded infected contacts whose *V. cholerae* serotype did not 332 match the index case and contacts with "possible infections" (i.e., stool negative with  $\geq$ 4-fold 333 increase in vibriocidal titer and/or diarrhea symptoms).

334

## 335 Human challenge trial in North American volunteers

We included samples and data from 67 North American volunteers with no history of cholera
 who were vaccinated with 5 x 10<sup>8</sup> colony-forming units (CFU) of the live attenuated oral cholera

vaccine CVD 103-HgR and then challenged with approximately 5 x 10<sup>5</sup> V. cholerae O1 EI Tor

Inaba strain N16961 on either 10 (n = 34) or 90 (n = 33) days post vaccination (Chen et al.,

340 2016). Challenged participants were monitored for diarrhea symptoms and each stool was

341 graded; all loose stools (grades 3-5) were weighed, and volumes calculated.

342

#### 343 Outcomes and definitions

344 Case-ascertainment cohorts in Dhaka, Bangladesh

345 The primary outcome in the household contacts cohort was *V. cholera* infection. Infection was

defined as developing a positive stool culture result on day 7 or 30 after enrollment of the

347 household's index cholera case. A secondary outcome among infected household contacts was

developing symptoms. Symptoms included watery diarrhea (≥3 loose or watery stools in a 24-hr

349 period), abdominal pain, vomiting, and/or fever.

350

351 Human challenge trial in North American volunteers

The primary outcome in the vaccine challenge cohort was developing symptomatic cholera diarrhea. Diarrhea was defined as  $\geq 2$  loose stools of  $\geq 200$  mL each or a single loose stool of  $\geq 300$  mL over a 48-hour period. Moderate diarrhea was passage of  $\geq 3$  L and severe diarrhea was passage of  $\geq 5$  L loose stool (Chen et al., 2016).

356

#### 357 Laboratory methods

358 Antigens

359 V. cholerae Inaba and Ogawa OSP:BSA conjugates, TcpA, and V. cholerae sialidase were

derived as previously described (Charles et al., 2017). V. cholerae holotoxin (List Biological,

361 catalog 100B) and CtxB (Sigma, catalog C9903) were purchased from commercial vendors as362 indicated.

363

364 Luminex assay for antigen-specific antibody responses

We measured antigen-specific Ig class (IgG, IgA, IgM) and subclass (IgG1, IgG2, IgG, IgG4,

366 IgA1, IgA2) responses against antigens using a customized Luminex assay. Each antigen was

367 conjugated to unique, phycoerythrin (PE)-labeled, MagPlex-C Microsphere (Luminex Corp,

368 Austin, TX) bead region at a concentration of 5  $\mu$ g antigen per 1 x 10<sup>6</sup> microspheres using the

369 principles of carbodiimide coupling and as per manufacturer's instructions (Luminex, xMAP®

370 Antibody Coupling kit, catalog 40-50016).

371

Plasma samples were heat-inactivated by incubation at 56°C for 30 minutes and diluted in an
assay buffer (0.1% BSA in 1X DPBS) to a final dilution of 1:100. Five µl of diluted plasma and
45 µl of diluted antigen-conjugated beads were added to a black 384-well polystyrene plate
(Greiner Bio-One<sup>™</sup>, Monroe, NC) at a final concentration of 15 beads per µl (total: 675 beads
per well). Plates were incubated overnight at 4°C with shaking (800 rpm) and then sonicated

377 and washed thrice with 0.1%BSA in 1X PBS, 0.05% Tween20 before addition of PE-conjugated 378 anti-human IgG, IgM and IgA (Southern Biotech; 40 µl per well) for a final dilution of 1:154. After 379 incubation at 1 hour with shaking, plates were sonicated and washed thrice with 0.1% BSA in 380 1X PBS, 0.05% Tween20. The beads were resuspended in 40µl of sheath fluid (Fisher 381 Scientific, Waltham, MA) and analyzed using Bioplex/Flexmap machines (BioRad). Samples 382 were tested in duplicate, and data were analyzed as geometric mean fluorescence intensities. 383 384 Antigen biotinylation 385 Ogawa OSP:BSA antigen (2 mg/ml stock) and Inaba OSP:BSA (2.5mg/ml) was biotinylated at 386 20mM excess as per manufacturer's instructions (Thermofisher Scientific, catalog: A39256)

followed by removal of unbound biotin using Zeba Spin column 7K MWCO (Thermofisher,

388 catalog: 89882).

389

390 Antibody-dependent neutrophil phagocytosis (ADNP assay)

391 Biotinylated Ogawa OSP:BSA antigen (2 mg/ml stock) and Inaba OSP:BSA (2.5mg/ml) was 392 conjugated with 1.0µm yellow/green fluorescent neutravidin labeled microspheres 393 (Thermofisher, catalog F8776) at 1:1 ratio and incubated at 37°C for 2 hours. The antigen-394 conjugated beads were pelleted, washed twice, and resuspended in 0.1% BSA in 1X DPBS and 395 used within 4 days. Ten µl of heat inactivated (56°C for 30 mins) plasma diluted 1:4 in 0.1% 396 BSA in 1X DPBS was added per well to a 96-well plate (Costar catalog:3799) followed by the 397 addition of 10 µl/well of antigen-bead conjugate. Plates were incubated at 37°C 5% CO<sub>2</sub> for 2 398 hours. 399

400 Blood collected from healthy donors was lysed using ammonium-chloride-potassium lysis buffer

401 (150 mM NH<sub>4</sub>Cl, 10 mM KHCO3, 0.1 mM Na<sub>2</sub>EDTA, pH 7.4) at 1:10 ratio and incubated for 5

402 mins at room temperature. Cells were pelleted at 500×g for 5 mins, washed with cold 1X DPBS

403 and resuspended in RPMI with 10% Fetal Calf Serum and 1X Penicillin/Streptomycin. 404 Granulocytes were resuspended at a concentration of 2.5 x 10<sup>5</sup> cells/ml. At the end of the 2-405 hour incubation, beads were pelleted, washed twice with 0.1% BSA in 1X DPBS and 406 supernatants flicked. 200ul of resuspended cells (50,000 total cells) were added per well to the 407 96-well plate and plates were incubated at 37°C for 4 hours. Cells were pelleted (5 min, 4°C, 408 500 ×g), stained with CD66b-PacBlue (Biolegend), washed, and fixed with 4% 409 paraformaldehyde. Samples were acquired within 48 hours on BD LSR Fortessa. 410 411 Neutrophil bead internalization was quantified using FlowJo (FlowJo, LLC) software by gating 412 for granulocytes (FSC/SSC)/neutrophils (CD66b+)/bead+neutrophils (FITC+). Phagocytic score 413 was calculated by multiplying the percentage of neutrophils that internalized the beads with 414 geometric mean fluorescence intensity of bead+ neutrophils+ cells divided by 10,000. Samples 415 were run in singlicate and results are an average of 3 independent experiments run using 3 416 different blood donors.

417

418 Antibody-dependent complement deposition (ADCD assay)

12 μl of biotinylated Ogawa OSP:BSA or Inaba OSP:BSA antigen was conjugated with 1.0 μm
red fluorescent, neutravidin labeled microspheres (Thermofisher, catalog F8775) per 96-well
plate at 37°C for 2 hours. The antigen:conjugated beads were pelleted and washed twice with
0.1%BSA in 1X DPBS followed by resuspension in 1200ul of 0.1% BSA in 1X DPBS. They were
used within 4 days.

424

Ten µl of heat inactivated (56°C for 30 mins) plasma diluted 1:4 in 5% BSA in 1X DPBS was
added to a 96-well plate (Costar catalog:3799) followed by the addition of 10 µl of antigen-bead
conjugate and incubation at 37°C, 5% CO<sub>2</sub>. Four µl of reconstituted guinea pig complement
(Cedarlane; catalog CL4051) diluted 1:50 in Gelatin Veronal Buffer was added per well to the

429 96-well plate and incubated at 37°C for 20 mins. At the end of incubation, beads were pelleted 430 at 2000×g for 10 mins and then washed twice with cold 15mM EDTA in 1X DPBS.

431

432 Fifty µl of FITC labeled goat anti-guinea pig C3 diluted 1:200 in 1X PBS was added to the plate 433 and incubated in the dark at room temperature for 15 mins. Plates were washed twice, and the 434 beads were resuspended in 100µl PBS. Geometric MFI of FITC gated on red, neutravidin beads 435 were calculated using FlowJo software. Samples were tested in singlicate and results are an 436 average of 3 independent experiments.

437

438 Antibody-dependent cellular phagocytosis

439 Ogawa antigen bead conjugates were prepared as described for the ADNP assay. THP-1 cells 440 were maintained in RPMI 1640 media (ATCC) containing 2 mM L-Glutamine (Corning), 10% 441 Fetal Bovine Serum (Sigma), 10 mM HEPES (Corning), 55 µM beta-mercaptoethanol (Gibco), 442 and 1X Penicillin/Streptomycin (Corning). A volume of 10 µL diluted human monoclonal 443 antibody or plasma sample was added to each well, and immune complexes were formed over 444 a 2-hour incubation at 37°C. After washing to remove non-specific unbound antibody, THP-1 445 cells were added (200  $\mu$ L/well) at a concentration of 1.25 × 10<sup>5</sup> cells/mL (2.5 × 10<sup>4</sup> cells/well) 446 and incubated with the immune complexed beads for 16 hours at 37°C. Cells were then fixed 447 with 4% PFA and acquired on a BD LSRFortessa flow cytometer. The phagocytic score was 448 calculated by multiplying the percentage of bead-positive cells by the geometric mean 449 fluorescence intensities of the bead-positive cells divided by 10,000. 450

451 Analytical methods

452 Single-marker correlates of infection

453 All analyses were performed in the R Statistical Software v4.0.3 (R Core Team, 2020). We

454 examined risk of infection (i.e., developing a positive stool culture result) among all household

455 contacts after exposure to an index cholera case, and risk of developing symptoms among
456 infected household contacts. Odds ratios of developing infection or symptomatic cholera for
457 each 2-fold increase in baseline biomarker titers were calculated using generalized estimating
458 equations using the gee package (Carey et al., 2019), adjusting for household clustering and
459 age. Biomarkers were centered and scaled prior to analysis. Biomarkers in logistic models with
460 fitted values very close to 1 were excluded.

461

462 Unsupervised analysis

463 We examined whether participants were separated by individual outcomes (V. cholerae

464 infection and cholera diarrhea) using generalized principal component analysis (GLM-PCA),

465 which allows for dimension reduction in non-normally distributed data. Analyses were run using

the glmpca package with a negative binomial likelihood (Townes et al., 2019).

467

## 468 Supervised analyses

469 We used conditional random forest models to examine which baseline biomarkers were most 470 important for classifying individuals that went on to develop infection vs. those that remained 471 uninfected and, of those infected, which went on to develop symptoms vs. which remained asymptomatic in the household contacts. We used the same approach to classify cholera 472 473 diarrhea vs. no qualifying diarrhea in the vaccine challenge cohort. Models were run with 1000 474 trees and class weights to account for imbalances in the data, and otherwise default settings 475 from the party package were used (Strobl et al., 2008, 2007). Conditional permutation 476 importance was used to rank variables via the perimp package (Debeer and Strobl, 2020).

477

We used leave-one-out cross-validation to examine the predictive validity of the conditional
random forest models for the outcomes described above using different subsets of biomarkers
and age. Predictions were visualized using receiver operator curves (cvROC) built using the

481	pROC package (Robin et al., 2011). The area under those curves (cvAUC) and corresponding
482	influence curve-based confidence intervals were calculated using the cvAUC package (LeDell et
483	al., 2014). In addition, we compared cvROC and cvAUC for the conditional random forest
484	models to that of an ensemble of three different machine learning models: random forest,
485	penalized logistic regression, and support vector machine. Analyses were run using class
486	weights to account for imbalances in the dataset and otherwise default settings in the
487	SuperLearner package (Polley et al., 2021).
488	
489	Data availability
490	All data generated in this study are available in the manuscript and Supplementary file 1. All
491	input datasets and analytical code are available at: https://github.com/HopkinsIDD/cholera-
492	systems-serology and https://doi.org/10.5281/zenodo.6626079.
493	
494	Acknowledgements
495	This research was supported by the icddr,b and extramural grants from the National Institutes of
496	Health, including the National Institute of Allergy and Infectious Diseases, (R01 Al137164
497	[J.B.H., R.C.C., G.A., F.Q.], R01 Al106878 [E.T.R., F.Q.], R01 Al130378 [T.R.B.], R01
498	AI135115 [A.S.A, K.E.W.]). icddr,b is thankful to the donors for their support to its research
499	efforts. icddr,b is also grateful to the governments of Bangladesh, Canada, Sweden, and the
500	United Kingdom for providing core/unrestricted support.
501	
502	Competing interests
503	The authors declare that they have no competing interests.
504	
505	Ethics

- 506 This study was approved by icddr,b Ethical Review Committee and Massachusetts General507 Hospital's Institutional Review Boards.
- 508

## 509 References

- 510 Arnold KB, Chung AW. 2018. Prospects from systems serology research. *Immunology*
- 511 **153**:279–289. doi:10.1111/imm.12861
- 512 Azman AS, Lessler J, Luquero FJ, Bhuiyan TR, Khan AI, Chowdhury F, Kabir A, Gurwith M,
- 513 Weil AA, Harris JB, Calderwood SB, Ryan ET, Qadri F, Leung DT. 2019. Estimating
- 514 cholera incidence with cross-sectional serology. *Science Translational Medicine* **11**.
- 515 doi:10.1126/scitranslmed.aau6242
- 516 Baranova DE, Levinson KJ, Mantis NJ. 2018. Vibrio cholerae O1 secretes an extracellular
- 517 matrix in response to antibody-mediated agglutination. *PLoS One* **13**:e0190026.
- 518 doi:10.1371/journal.pone.0190026
- 519 Bartsch YC, Wang C, Zohar T, Fischinger S, Atyeo C, Burke JS, Kang J, Edlow AG, Fasano A,
- 520 Baden LR, Nilles EJ, Woolley AE, Karlson EW, Hopke AR, Irimia D, Fischer ES, Ryan
- 521 ET, Charles RC, Julg BD, Lauffenburger DA, Yonker LM, Alter G. 2021. Humoral
- 522 signatures of protective and pathological SARS-CoV-2 infection in children. *Nat Med*
- 523 **27**:454–462. doi:10.1038/s41591-021-01263-3
- 524 Carey VJ, Lumley T, Ripley B, Moler C. 2019. gee: generalized estimation equation solver. R
  525 package version 4.13-20.
- 526 Charles RC, Nakajima R, Liang L, Jasinskas A, Berger A, Leung DT, Kelly M, Xu P, Kováč P,
- 527 Giffen SR, Harbison JD, Chowdhury F, Khan AI, Calderwood SB, Bhuiyan TR, Harris JB,
- 528 Felgner PL, Qadri F, Ryan ET. 2017. Plasma and mucosal immunoglobulin M,
- 529 immunoglobulin A, and immunoglobulin G responses to the Vibrio cholerae O1 protein

- 530 immunome in adults with cholera in Bangladesh. The Journal of Infectious Diseases
- 531 **216**:125–134. doi:10.1093/infdis/jix253

532 Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA,

- 533 Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM.
- 534 2016. Single-dose live oral cholera vaccine CVD 103-HgR protects against human
- 535 experimental infection With Vibrio cholerae O1 El Tor. *Clinical Infectious Diseases*
- 536 **62**:1329–1335. doi:10.1093/cid/ciw145
- 537 Chung AW, Alter G. 2017. Systems serology: profiling vaccine induced humoral immunity

538 against HIV. *Retrovirology* **14**:57. doi:10.1186/s12977-017-0380-3

- 539 Coit J, Mendoza M, Pinedo C, Marin H, Chiang SS, Lecca L, Franke M. 2019. Performance of a
- 540 household tuberculosis exposure survey among children in a Latin American setting.
- 541 The International Journal of Tuberculosis and Lung Disease **23**:1223–1227.
- 542 doi:10.5588/ijtld.18.0841
- 543 Debeer D, Strobl C. 2020. Conditional permutation importance revisited. *BMC Bioinformatics*
- 544 **21**:307. doi:10.1186/s12859-020-03622-2
- 545 Haney DJ, Lock MD, Gurwith M, Simon JK, Ishioka G, Cohen MB, Kirkpatrick BD, Lyon CE,
- 546 Chen WH, Sztein MB, Levine MM, Harris JB. 2018. Lipopolysaccharide-specific memory
- 547 B cell responses to an attenuated live cholera vaccine are associated with protection
- 548 against Vibrio cholerae infection. *Vaccine* **36**:2768–2773.
- 549 doi:10.1016/j.vaccine.2018.04.011

Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque ASG, Ryan ET, Qadri

- 551 F, Calderwood SB. 2008. Susceptibility to Vibrio cholerae infection in a cohort of
- bousehold contacts of patients with cholera in Bangladesh. *PLOS Neglected Tropical*
- 553 *Diseases* **2**:e221. doi:10.1371/journal.pntd.0000221
- 554 Iyer AS, Harris JB. 2021. Correlates of protection for cholera. The Journal of Infectious
- 555 *Diseases* **224**:S732–S737. doi:10.1093/infdis/jiab497

- Jin C, Hill J, Gunn BM, Yu W-H, Dahora LC, Jones E, Johnson M, Gibani MM, Spreng RL, Alam
  SM, Nebykova A, Juel HB, Dennison SM, Seaton KE, Fallon JK, Tomaras GD, Alter G,
  Pollard AJ. 2020. Vi-specific serological correlates of protection for typhoid fever. *J Exp Med* 218:e20201116. doi:10.1084/jem.20201116
- Kaisar MH, Bhuiyan MS, Akter A, Saleem D, Iyer AS, Dash P, Hakim A, Chowdhury F, Khan AI,
  Calderwood SB, Harris JB, Ryan ET, Qadri F, Charles RC, Bhuiyan TR. 2021. Vibrio
  cholerae sialidase-specific immune responses are associated with protection against
  cholera. *mSphere* 6:e01232-20. doi:10.1128/mSphere.01232-20
- 564 Karlsson EK, Harris JB, Tabrizi S, Rahman A, Shlyakhter I, Patterson N, O'Dushlaine C,
- 565 Schaffner SF, Gupta S, Chowdhury F, Sheikh A, Shin OS, Ellis C, Becker CE, Stuart
- 566 LM, Calderwood SB, Ryan ET, Qadri F, Sabeti PC, LaRocque RC. 2013. Natural

selection in a Bangladeshi population from the cholera-endemic Ganges River Delta.

568 Science Translational Medicine 5:192ra86-192ra86. doi:10.1126/scitranslmed.3006338

569 Kauffman RC, Bhuiyan TR, Nakajima R, Mayo-Smith LM, Rashu R, Hoq MR, Chowdhury F,

570 Khan AI, Rahman A, Bhaumik SK, Harris L, O'Neal JT, Trost JF, Alam NH, Jasinskas A,

571 Dotsey E, Kelly M, Charles RC, Xu P, Kováč P, Calderwood SB, Ryan ET, Felgner PL,

- 572 Qadri F, Wrammert J, Harris JB. 2016. Single-cell analysis of the plasmablast response
- 573 to Vibrio cholerae demonstrates expansion of cross-reactive memory B cells. *mBio*

574 **7**:e02021-16. doi:10.1128/mBio.02021-16

575 LeDell E, Petersen M, Laan M van der. 2014. cvAUC: cross-validated area under the ROC
576 curve confidence intervals.

577 Levade I, Saber MM, Midani FS, Chowdhury F, Khan AI, Begum YA, Ryan ET, David LA,

578 Calderwood SB, Harris JB, LaRocque RC, Qadri F, Shapiro BJ, Weil AA. 2021.

579 Predicting Vibrio cholerae infection and disease severity using metagenomics in a

580 prospective cohort study. J Infect Dis 223:342–351. doi:10.1093/infdis/jiaa358

- Lu LL, Chung AW, Rosebrock T, Ghebremichael M, Yu WH, Grace PS, Schoen MK, Tafesse F,
- 582 Martin C, Leung V, Mahan AE, Sips M, Kumar M, Tedesco J, Robinson H, Tkachenko E,
- 583 Draghi M, Freedberg KJ, Streeck H, Suscovich TJ, Lauffenburger D, Restrepo BI, Day
- 584 C, Fortune SM, Alter G. 2016. A functional role for antibodies in tuberculosis. *Cell*
- 585 **167**:433-443.e14. doi:10.1016/j.cell.2016.08.072
- 586 McGill R, Tukey JW, Larsen WA. 1978. Variations of box plots. *The American Statistician*587 **32**:12–16. doi:10.2307/2683468
- 588 Midani FS, Weil AA, Chowdhury F, Begum YA, Khan AI, Debela MD, Durand HK, Reese AT,
- 589 Nimmagadda SN, Silverman JD, Ellis CN, Ryan ET, Calderwood SB, Harris JB, Qadri F,
- 590 David LA, LaRocque RC. 2018. Human gut microbiota predicts susceptibility to Vibrio
- 591 cholerae infection. *J Infect Dis* **218**:645–653. doi:10.1093/infdis/jiy192
- 592 Patel SM, Rahman MA, Mohasin M, Riyadh MA, Leung DT, Alam MM, Chowdhury F, Khan AI,
- 593 Weil AA, Aktar A, Nazim M, LaRocque RC, Ryan ET, Calderwood SB, Qadri F, Harris
- 594 JB. 2012. Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are
- associated with protection against infection from household contacts of patients with
- 596 cholera in Bangladesh. *Clinical and Vaccine Immunology* **19**:842–848.
- 597 doi:10.1128/CVI.00037-12
- Polley E, LeDell E, Kennedy C, Lendle S, Laan M van der. 2021. SuperLearner: super learner
   prediction.
- R Core Team. 2020. R: a language and environment for statistical computing. R Foundation for
   Statistical Computing, Vienna, Austria.
- Ritter AS, Chowdhury F, Franke MF, Becker RL, Bhuiyan TR, Khan AI, Saha NC, Ryan ET,
- 603 Calderwood SB, LaRocque RC, Harris JB, Qadri F, Weil AA. 2019. Vibriocidal titer and
- 604 protection from cholera in children. *Open Forum Infectious Diseases* **6**.
- 605 doi:10.1093/ofid/ofz057

- Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M. 2011. pROC: an
- 607 open-source package for R and S+ to analyze and compare ROC curves. *BMC*608 *Bioinformatics* 12:77. doi:10.1186/1471-2105-12-77
- Strobl C, Boulesteix A-L, Kneib T, Augustin T, Zeileis A. 2008. Conditional variable importance
  for random forests. *BMC Bioinformatics* 9:307. doi:10.1186/1471-2105-9-307
- 611 Strobl C, Boulesteix A-L, Zeileis A, Hothorn T. 2007. Bias in random forest variable importance
- 612 measures: Illustrations, sources and a solution. *BMC Bioinformatics* **8**:25.
- 613 doi:10.1186/1471-2105-8-25
- Townes FW, Hicks SC, Aryee MJ, Irizarry RA. 2019. Feature selection and dimension reduction
- for single-cell RNA-Seq based on a multinomial model. *Genome Biology* **20**:295.
- 616 doi:10.1186/s13059-019-1861-6
- 617 Weil AA, Becker RL, Harris JB. 2019. Vibrio cholerae at the intersection of immunity and the 618 microbiome. *mSphere* **4**. doi:10.1128/mSphere.00597-19
- 619 Weil AA, Khan AI, Chowdhury F, LaRocque RC, Faruque ASG, Ryan ET, Calderwood SB,
- 620 Qadri F, Harris JB. 2009. Clinical outcomes in household contacts of patients with
- 621 cholera in Bangladesh. *Clin Infect Dis* **49**:1473–1479. doi:10.1086/644779